Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
Holding SAVA?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.58Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Sell
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2018
|% Change Since: -89.88%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mix of promising progress in clinical trials and financial stability, but also highlighted increased administrative costs and legal challenges. The anticipation of Phase III trial results is a critical point of focus.Company Guidance
During Cassava Sciences' Q3 2024 earnings call, CEO Richard Barry provided guidance on the company's upcoming milestones and financial outlook. He emphasized the anticipated release of top-line results from the Phase III RETHINK-ALZ trial before the end of the year, highlighting the potential for a best-in-class treatment for Alzheimer's disease. The company plans to report biomarker data for approximately 100 patients, focusing on plasma markers such as pTau 217, Neurofilament Light Chain (NFL), Glial Fibrillary Acidic Protein (GFAP), and total tau. Financially, Cassava Sciences ended the quarter with $149 million in cash, which is expected to be sufficient for operations through the conclusion of ongoing Phase III trials and into 2026. Net cash used in operations for the first nine months of 2024 was $55.7 million, with projections for the second half ranging between $80 million and $90 million, inclusive of a $40 million SEC settlement. The company's net loss for Q3 was $27.9 million, with R&D expenses decreasing as more patients transition to a lower-cost open-label study.Phase III Trial Progress
Announced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
Cash Position and Financial Stability
Ended Q3 with $149 million in cash, expected to fund operations through the conclusion of ongoing Phase III trials and into 2026.
Reduced R&D Expenses
R&D expenses for Q3 were $17.7 million, down from $23.6 million in the same period last year as more patients transition from Phase III to lower-cost open-label studies.
Biomarker Innovation
Discussed the potential of plasma biomarker tests with high correlation to Alzheimer's diagnosis, which could transform treatment by primary care physicians.
---
SAVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SAVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $26.57 | $25.34 | -4.63% |
| Aug 08, 2024 | $30.20 | $26.02 | -13.84% |
| May 10, 2024 | $20.23 | $20.62 | +1.93% |
| Feb 28, 2024 | $23.00 | $22.93 | -0.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cassava Sciences (SAVA) report earnings?
Cassava Sciences (SAVA) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Cassava Sciences (SAVA) earnings time?
Cassava Sciences (SAVA) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SAVA EPS forecast?
SAVA EPS forecast for the fiscal quarter 2024 (Q4) is -0.58.
---